We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.


BrainStorm Cell Therapeutics Initiates Stem Cell Safety Study in Primates for Parkinson’s Disease

Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: Less than a minute

BrainStorm Cell Therapeutics has announced that it has initiated a safety trial using an animal model of Parkinson’s disease in primates.

The study utilizes BrainStorm’s adult stem cell technology which has shown efficacy in animal models of Parkinson’s Disease in previous pre-clinical trials.

In those studies, human-bone-marrow-derived stem cells were differentiated into astrocyte-like cells (supporting cells) and transplanted into mice and rats brains. The engrafted cells survived, kept their function and significantly improved the motor symptoms of Parkinson's Disease animal models over a long period of time.

The study is being carried out in collaboration with the Center for Applied Medical Research (CIMA) of the University of Navarra in Pamplona, Spain. The team at the Movement Disorders Unit at the University has over 20 years experience in researching and applying new therapies to treat Parkinson’s Disease, and anticipates being among the first to use BrainStorm’s technology to treat patients in its own University Hospital.

Commenting on the announcement, Yoram Drucker, BrainStorm Cell Therapeutic’s Chief Operating Officer stated: “We are pleased to have this primate safety study underway and we anticipate that successful results will lead to human clinical trials.”

In addition to moving ahead with the company’s Parkinson’s Disease program, BrainStorm is also progressing with pre-clinical trials applying the company’s stem cell technology to the treatment of ALS and Multiple Sclerosis.